Luz Melisa Moreno Mena

Complex multimorbidity has become a defining feature of contemporary internal medicine, particularly within inflammatory–metabolic intersections such as dermatologic and endocrine disorders. As chronic conditions cluster in structured cardiometabolic networks, traditional disease-specific guideline approaches increasingly generate therapeutic conflict, polypharmacy, and reduced predictive accuracy in high-complexity patients. This study developed and evaluated an integrated precision decision-making framework designed to reconcile inflammatory burden, endocrine dysregulation, cardiovascular risk stratification, medication safety, and patient-centered prioritization within a unified clinical model. Multidimensional analysis demonstrated coherent cardiometabolic clustering with measurable inflammatory–metabolic overlap. As multimorbidity complexity increased, medication burden, adverse drug event risk, and guideline conflict rose progressively under traditional management approaches, while predictive discrimination declined. In contrast, the integrated precision framework showed lower conflict indices and improved predictive performance across escalating strata of complexity. Outcome prioritization analysis revealed a structured distribution balancing cardiovascular stabilization, metabolic control, inflammatory skin management, polypharmacy reduction, and quality-of-life considerations. These findings support the transition from fragmented, disease-centered optimization toward an integrated, value-based, and precision-guided model of internal medicine capable of addressing the biological and therapeutic interdependence characteristic of complex chronic disease networks.

Low-grade inflammation has emerged as a central biological mechanism linking multiple chronic conditions commonly encountered in internal medicine. Increasing evidence indicates that metabolic and cardiovascular diseases are not isolated entities, but interconnected manifestations of a shared immunometabolic dysfunction. In this context, type 2 diabetes mellitus occupies a pivotal role, functioning both as a consequence and a driver of chronic inflammatory activation. This narrative review synthesizes experimental, epidemiological, and clinical evidence to analyze low-grade inflammation as a cross-cutting mechanism underlying chronic disease, with particular emphasis on its relationship with insulin resistance, metabolic dysregulation, and cardiovascular risk. The findings demonstrate a progressive increase in inflammatory burden across the metabolic continuum, a close association between inflammation and insulin resistance, and a consistent convergence between inflammatory activity and cardiovascular risk. These patterns are preserved across different population contexts, supporting the global relevance of inflammation-centered models of chronic disease. Conceptualizing diabetes as an immunometabolic disorder within this framework offers an integrative perspective that may enhance clinical reasoning, prevention strategies, and medical education in internal medicine.

Systemic low-grade inflammation has emerged as a central biological mechanism underlying the development and progression of major chronic non-communicable diseases. This integrative review analyzes mechanistic, epidemiological, and interventional evidence supporting inflammation as a unifying pathophysiological axis, with particular emphasis on cardiovascular disease. Foundational immunological frameworks describe nonresolving inflammation as a driver of endothelial dysfunction, cytokine amplification, metabolic dysregulation, and tissue remodeling. In atherosclerotic cardiovascular disease, inflammatory signaling within the arterial wall contributes to plaque instability and thrombo-inflammatory activation, and clinical trial data demonstrate that targeted anti-inflammatory therapy can reduce recurrent cardiovascular events in selected populations. Parallel evidence from immunometabolic research links obesity and type 2 diabetes to chronic inflammatory activation, reinforcing the interconnected immune–metabolic–vascular model. The review also addresses inflammaging and multimorbidity, highlighting how sustained inflammatory tone increases vulnerability to cardiometabolic and systemic disease across the lifespan. Translational implications include biomarker-guided risk stratification, recognition of residual inflammatory risk, and integration of lifestyle and pharmacologic strategies aimed at modulating inflammatory burden. From an international perspective, particularly in middle-income countries experiencing epidemiological transition, understanding systemic inflammation as a shared biological substrate may support more integrated prevention and management strategies within internal medicine.